Literature DB >> 11898583

Aminoglycoside treatment for muscular dystrophy is scientifically rational, but is it clinically effective?

Michio Hirano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11898583     DOI： 10.1007/s11910-002-0053-y

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  5 in total

1.  When running a stop sign may be a good thing.

Authors:  G Karpati; H Lochmuller
Journal:  Ann Neurol       Date:  2001-06       Impact factor: 10.422

2.  Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis.

Authors:  J P Clancy; Z Bebök; F Ruiz; C King; J Jones; L Walker; H Greer; J Hong; L Wing; M Macaluso; R Lyrene; E J Sorscher; D M Bedwell
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

3.  Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice.

Authors:  E R Barton-Davis; L Cordier; D I Shoturma; S E Leland; H L Sweeney
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

4.  A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations.

Authors:  M Wilschanski; C Famini; H Blau; J Rivlin; A Augarten; A Avital; B Kerem; E Kerem
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

5.  Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin.

Authors:  J F Burke; A E Mogg
Journal:  Nucleic Acids Res       Date:  1985-09-11       Impact factor: 16.971
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.